trending Market Intelligence /marketintelligence/en/news-insights/trending/5JBzZrh1Ao5mvB6S0LMqFQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Charles River agrees to acquire biological services provider HemaCare for $380M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Charles River agrees to acquire biological services provider HemaCare for $380M

Charles River Laboratories International Inc. has agreed to acquire biological services provider HemaCare Corp. for $380 million in cash.

Wilmington, Mass.-based Charles River, a contract research company, is paying $25.40 per share, a 27% surplus to HemaCare's stock closing price Dec. 13.

HemaCare produces human cellular products, which support medical research and drug development, for use in the cell therapy market. Charles River said the acquisition will complement its portfolio of early-stage research and manufacturing products. The company expects the acquisition, which is expected to close in the first quarter of 2020, to increase revenue by at least 30% annually over the next five years.

The deal will be financed through Charles River's existing credit facility and cash.

BofA Securities is acting as Charles River's financial adviser, while Davis Polk & Wardwell LLP is providing transactional legal counsel and Axinn Veltrop & Harkrider LLP is acting as antitrust counsel. Jefferies LLC is acting as HemaCare's financial adviser, and Greenberg Traurig LLP is transactional legal counsel.

S&P Global Ratings downgraded Charles River's issuer credit rating to BB+ in May following the April acquisition of Citoxlab.